Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1158/1078-0432.CCR-08-1390 http://scihub22266oqcxt.onion/10.1158/1078-0432.CCR-08-1390 19010875!ä!19010875 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Cancer+Res 2008 ; 14 (22): 7564-8 Nephropedia Template TP {{tp|p=19010875|t=2008. Nuclear factor-kappaB modulation in patients undergoing induction chemotherapy for acute myelogenous leukemia |pdf=|usr=}}{{19010875}} gab.com Text Nuclear factor-kappaB modulation in patients undergoing induction chemotherapy for acute myelogenous leukemia JO: Clin Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=19010875 #FOAvip PURPOSE: Nuclear factor-kappaB (NF-kappaB) is constitutively expressed in many acute myelogenous leukemia (AML) cells and AML stem cells. Ex vivo treatment of AML cells with inhibitors of NF-kappaB results in diminished AML cell survival and enhances the cytotoxic effects of chemotherapeutic agents. The purpose of this study was to determine if standard anti-inflammatory agents modulate AML cell nuclear NF-kappaB when administered in conjunction with induction chemotherapy. EXPERIMENTAL DESIGN: Patients with newly diagnosed AML were treated with dexamethasone, choline magnesium trisalicylate, or both for 24 hours prior to and 24 hours following initiation of standard induction chemotherapy. AML cell nuclear NF-kappaB was measured at baseline, 24, and 48 hours. RESULTS: Choline magnesium trisalicylate +/- dexamethasone decreased nuclear NF-kappaB, whereas dexamethasone alone was associated with an increase in nuclear NF-kappaB in AML cells. CONCLUSIONS: These results show the feasibility of NF-kappaB modulation in conjunction with induction chemotherapy for patients with AML using inexpensive readily available medications. A follow-up study to determine the effects of NF-kappaB modulation on clinical end points is warranted. Twit Text FOAVip Nuclear factor-kappaB modulation in patients undergoing induction chemotherapy for acute myelogenous leukemia ????Clin Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=19010875 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=19010875 #FOAvip English Wikipedia <ref>{{Cite pmid|19010875}}</ref> Nuclear factor-kappaB modulation in patients undergoing induction chemotherapy for acute myelogenous leukemia #MMPMID19010875 Strair RK; Gharibo M; Schaar D; Rubin A; Harrison J; Aisner J; Lin HC; Lin Y; Goodell L; Anand M; Balsara B; Dudek L; Rabson A; Medina DJ Clin Cancer Res 2008[Nov]; 14 (22): 7564-8 PMID19010875show ga PURPOSE: Nuclear factor-kappaB (NF-kappaB) is constitutively expressed in many acute myelogenous leukemia (AML) cells and AML stem cells. Ex vivo treatment of AML cells with inhibitors of NF-kappaB results in diminished AML cell survival and enhances the cytotoxic effects of chemotherapeutic agents. The purpose of this study was to determine if standard anti-inflammatory agents modulate AML cell nuclear NF-kappaB when administered in conjunction with induction chemotherapy. EXPERIMENTAL DESIGN: Patients with newly diagnosed AML were treated with dexamethasone, choline magnesium trisalicylate, or both for 24 hours prior to and 24 hours following initiation of standard induction chemotherapy. AML cell nuclear NF-kappaB was measured at baseline, 24, and 48 hours. RESULTS: Choline magnesium trisalicylate +/- dexamethasone decreased nuclear NF-kappaB, whereas dexamethasone alone was associated with an increase in nuclear NF-kappaB in AML cells. CONCLUSIONS: These results show the feasibility of NF-kappaB modulation in conjunction with induction chemotherapy for patients with AML using inexpensive readily available medications. A follow-up study to determine the effects of NF-kappaB modulation on clinical end points is warranted. |Adult[MESH] |Aged[MESH] |Anti-Inflammatory Agents/*administration & dosage[MESH] |Antineoplastic Combined Chemotherapy Protocols/therapeutic use[MESH] |Cell Nucleus/drug effects/metabolism[MESH] |Choline/administration & dosage/*analogs & derivatives[MESH] |Dexamethasone/*administration & dosage[MESH] |Enzyme-Linked Immunosorbent Assay[MESH] |Female[MESH] |Humans[MESH] |Leukemia, Myeloid, Acute/*drug therapy[MESH] |Male[MESH] |Middle Aged[MESH] |NF-kappa B/*biosynthesis/drug effects[MESH]Nuclear factor-kappaB modulation in patients undergoing induction chem(epmc).pdf DeepDyve Pubget Overpricing